These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 26037279)

  • 1. Blood and tissue neuroendocrine tumor gene cluster analysis correlate, define hallmarks and predict disease status.
    Kidd M; Drozdov I; Modlin I
    Endocr Relat Cancer; 2015 Aug; 22(4):561-75. PubMed ID: 26037279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroendocrine Tumor Omic Gene Cluster Analysis Amplifies the Prognostic Accuracy of the NETest.
    Kidd M; Kitz A; Drozdov I; Modlin I
    Neuroendocrinology; 2021; 111(5):490-504. PubMed ID: 32392558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors.
    Bodei L; Kidd M; Modlin IM; Severi S; Drozdov I; Nicolini S; Kwekkeboom DJ; Krenning EP; Baum RP; Paganelli G
    Eur J Nucl Med Mol Imaging; 2016 May; 43(5):839-851. PubMed ID: 26596723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical utility of circulating neuroendocrine gene transcript analysis in well-differentiated paragangliomas and pheochromocytomas.
    Pęczkowska M; Cwikla J; Kidd M; Lewczuk A; Kolasinska-Ćwikła A; Niec D; Michałowska I; Prejbisz A; Januszewicz A; Chiarelli J; Bodei L; Modlin I
    Eur J Endocrinol; 2017 Feb; 176(2):143-157. PubMed ID: 27913608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The utility of blood neuroendocrine gene transcript measurement in the diagnosis of bronchopulmonary neuroendocrine tumours and as a tool to evaluate surgical resection and disease progression.
    Filosso PL; Kidd M; Roffinella M; Lewczuk A; Chung KM; Kolasinska-Cwikla A; Cwikla J; Lowczak A; Doboszynska A; Malczewska A; Catalano M; Zunino V; Boita M; Arvat E; Cristofori R; Guerrera F; Oliaro A; Tesselaar M; Buikhuisen W; Kos-Kudla B; Papotti M; Bodei L; Drozdov I; Modlin I
    Eur J Cardiothorac Surg; 2018 Mar; 53(3):631-639. PubMed ID: 29145657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NET Blood Transcript Analysis Defines the Crossing of the Clinical Rubicon: When Stable Disease Becomes Progressive.
    Pavel M; Jann H; Prasad V; Drozdov I; Modlin IM; Kidd M
    Neuroendocrinology; 2017; 104(2):170-182. PubMed ID: 27078712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood measurement of neuroendocrine gene transcripts defines the effectiveness of operative resection and ablation strategies.
    Modlin IM; Frilling A; Salem RR; Alaimo D; Drymousis P; Wasan HS; Callahan S; Faiz O; Weng L; Teixeira N; Bodei L; Drozdov I; Kidd M
    Surgery; 2016 Jan; 159(1):336-47. PubMed ID: 26456125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating Transcript Analysis (NETest) in GEP-NETs Treated With Somatostatin Analogs Defines Therapy.
    Ćwikła JB; Bodei L; Kolasinska-Ćwikła A; Sankowski A; Modlin IM; Kidd M
    J Clin Endocrinol Metab; 2015 Nov; 100(11):E1437-45. PubMed ID: 26348352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract.
    Modlin IM; Kidd M; Bodei L; Drozdov I; Aslanian H
    Am J Gastroenterol; 2015 Aug; 110(8):1223-32. PubMed ID: 26032155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection.
    Modlin IM; Drozdov I; Alaimo D; Callahan S; Teixiera N; Bodei L; Kidd M
    Endocr Relat Cancer; 2014 Aug; 21(4):615-28. PubMed ID: 25015994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood Chromogranin A Is Not Effective as a Biomarker for Diagnosis or Management of Bronchopulmonary Neuroendocrine Tumors/Neoplasms.
    Matar S; Malczewska A; Oberg K; Bodei L; Aslanian H; Lewczuk-Myślicka A; Filosso PL; Suarez AL; Kolasińska-Ćwikła A; Roffinella M; Kos-Kudła B; Ćwikła JB; Drozdov IA; Kidd M; Modlin IM
    Neuroendocrinology; 2020; 110(3-4):185-197. PubMed ID: 30995665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chromogranin A: any relevance in neuroendocrine tumors?
    Kidd M; Bodei L; Modlin IM
    Curr Opin Endocrinol Diabetes Obes; 2016 Feb; 23(1):28-37. PubMed ID: 26627724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroendocrine tumor biomarkers: From monoanalytes to transcripts and algorithms.
    Modlin IM; Bodei L; Kidd M
    Best Pract Res Clin Endocrinol Metab; 2016 Jan; 30(1):59-77. PubMed ID: 26971844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of a ready-to-use PCR system for neuroendocrine tumor diagnosis.
    Kidd M; Drozdov IA; Matar S; Gurunlian N; Ferranti NJ; Malczewska A; Bennett P; Bodei L; Modlin IM
    PLoS One; 2019; 14(6):e0218592. PubMed ID: 31247038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Principal component analysis, hierarchical clustering, and decision tree assessment of plasma mRNA and hormone levels as an early detection strategy for small intestinal neuroendocrine (carcinoid) tumors.
    Modlin IM; Gustafsson BI; Drozdov I; Nadler B; Pfragner R; Kidd M
    Ann Surg Oncol; 2009 Feb; 16(2):487-98. PubMed ID: 19050963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of NETest Clinical Utility in a U.S. Registry-Based Study.
    Liu E; Paulson S; Gulati A; Freudman J; Grosh W; Kafer S; Wickremesinghe PC; Salem RR; Bodei L
    Oncologist; 2019 Jun; 24(6):783-790. PubMed ID: 30158287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
    Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
    J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NETest Liquid Biopsy Is Diagnostic of Lung Neuroendocrine Tumors and Identifies Progressive Disease.
    Malczewska A; Oberg K; Bodei L; Aslanian H; Lewczuk A; Filosso PL; Wójcik-Giertuga M; Rydel M; Zielińska-Leś I; Walter A; Suarez AL; Kolasińska-Ćwikła A; Roffinella M; Jamidar P; Ziora D; Czyżewski D; Kos-Kudła B; Ćwikła J
    Neuroendocrinology; 2019; 108(3):219-231. PubMed ID: 30654372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumors.
    Malczewska A; Kos-Kudła B; Kidd M; Drozdov I; Bodei L; Matar S; Oberg K; Modlin IM
    Adv Med Sci; 2020 Mar; 65(1):18-29. PubMed ID: 31841822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Genomic Assessment Using a Blood-based mRNA Signature (NETest) is Cost-effective and Predicts Neuroendocrine Tumor Recurrence With 94% Accuracy.
    Modlin IM; Kidd M; Frilling A; Falconi M; Filosso PL; Malczewska A; Kitz A
    Ann Surg; 2021 Sep; 274(3):481-490. PubMed ID: 34183517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.